In light of the large number of studies published since the 2004 update of Schizophrenia
Patient Outcomes Research Team psychopharmacological treatment recommendations, we …

Today's researchers are obligated to conduct their studies ethically. However, it often seems
a daunting task to become familiar with the important ethical codes required to do so. The …

In vivo measurement of neurotransmitters and modulators is now feasible with advanced
proton magnetic resonance spectroscopy (1 H MRS) techniques. This review provides a …

The participants in the NIMH-MATRICS Consensus Development Conference on Negative
Symptoms recommended that an instrument be developed that measured blunted affect …

BACKGROUND: Previous studies indicate that negative symptoms reflect a separable
domain of pathology from other symptoms of schizophrenia. However, it is currently unclear …

The current study examined the psychometric properties of the Brief Negative Symptom
Scale (BNSS), a next-generation rating instrument developed in response to the NIMH …

The current study examined the factor structure of the Brief Negative Symptom Scale
(BNSS), a next-generation negative symptom rating instrument developed in response to the …

Importance Less than one-third of patients with major depressive disorder (MDD) achieve
remission with their first antidepressant. Objective To determine the relative effectiveness …

Kraepelin proposed dementia praecox and manic-depressive illness as the two major
psychotic disorders. This paradigm is still prevalent, but observations of overlapping …

Objective Clozapine is the most effective antipsychotic for treatment refractory people with
schizophrenia, yet many patients only partially respond. Accumulating preclinical and …